Matrix Partners
Matrix Partners is a venture capital firm founded in 1977 and based in San Francisco that backs early-stage and Series A technology companies across sectors such as artificial intelligence, B2B software, consumer technology, fintech, health tech, infrastructure, and semiconductors. The firm emphasizes practical, founder-centered collaboration, often supporting concepts from idea stage through Series A and taking board seats to help portfolio companies scale. It operates globally, including Matrix Partners China, which focuses on long-term relationships with entrepreneurs in China and has a track record of IPOs and strategic exits. The team combines former founders and experienced investors to bring local execution and global perspective. Notable investments span across the technology landscape, reflecting a history of involvement with companies like FedEx, Apple, Oculus, Canva, Zendesk, HubSpot, Postmates, Fivetran, Sila, and GOAT, illustrating the firm’s ability to support companies from early development to scale.
Top Sectors
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Biotechnology
Centaur Labs
Series B in 2024
Centaur Labs provides a platform for expert data annotation services, specializing in medical, scientific, and other complex datasets. It leverages a global network of tens of thousands of students and professionals to deliver accurate and scalable solutions.
D3 Bio
Series A in 2024
D3 Bio, established in 2020, is a biotechnology company headquartered in China. It specializes in the development and registration of innovative medicines, primarily focusing on oncology and immunology. The company's approach involves analyzing clinical and market data to identify gaps in current treatments, employing unique drug development methodologies to target new disease areas and routes, and ultimately providing patients with alternative therapeutic options.
Alioth
Series A in 2023
Alioth specializes in the development and application of pharmaceutical process technology, focusing on high-quality separation and purification solutions for the pharmaceutical and biotechnology sectors. The company is committed to ensuring compliance with domestic and international regulations, particularly Good Manufacturing Practices (GMP). To support its operations, Alioth has established production facilities in Lingang, Shanghai, and Hangzhou, which house process development labs, verification labs, and research and development centers dedicated to filtration technology. The team, comprised of membrane technology scientists, plays a crucial role in advancing the company’s product offerings and enhancing supply chain security. Through its innovative solutions, Alioth aims to improve pharmaceutical manufacturing processes for its partners.
GRIT Biotechnology
Series B in 2023
GRIT Biotechnology, established in 2019 and based in Shanghai, China, specializes in the research and development of Tumor Infiltration Lymphocytes (TIL) immunotherapy for treating solid tumors. The company aims to enhance cancer therapies by focusing on this innovative approach.
Ucello Therapeutics
Series A in 2023
Ucello Therapeutics focuses on the development of allogeneic cell therapies utilizing its proprietary CAR-T cell technology platform, known as CBT-X20. The company aims to create universal CAR-T cell therapeutic drugs that address unmet clinical needs in cancer treatment. By leveraging advanced gene and cell therapy technologies, Ucello's therapies target cancer cells at the molecular level, making them accessible to patients with varying lymphocyte levels and those with a history of transplant relapse. This innovative approach allows for effective cancer gene therapies to be administered to individuals with specific pre-existing medical conditions.
Zenshine Pharma
Series B in 2023
Zenshine Pharma is a clinical-stage biopharmaceutical company with a focus on the development of small molecule drugs for cancer, viral infections, and autoimmune diseases.
Ouli Biomedical
Seed Round in 2023
Ouli Biomedical is a pharmaceutical company. They offer nucleic acid drug discovery, laboratory research and development, process and analysis development, CMC services, API production, and drug registration.
Levostar Biotechnology
Seed Round in 2023
Levostar Biotechnology is a biotechnology company focused on the development and manufacture of cell and gene therapy products. It offers comprehensive solutions for the cell and gene therapy industry, including clinical testing services for various therapy platforms, viral vector platforms, mRNA vaccines, and therapeutic platforms. The company emphasizes GMP-level production processes and stringent quality control methods for plasmids and mRNAs. By providing these advanced technologies and services, Levostar aims to facilitate and accelerate research and development in gene cell therapy and mRNA drug innovation.
Insyce
Series B in 2023
Insyce creates equipment and apparatus for science. Its business strives to provide tools and technology for bio labs that monitor the environment to deliver accurate data and speedy chemical analysis while keeping lab costs down for their clients. It is dedicated to providing upper biological separation equipment and chemical analysis tools for global clients, cutting down on client operating expenses, and adding value for clients.
Rgenta Therapeutics
Series A in 2022
Rgenta Therapeutics, Inc. is a biotechnology company focused on developing RNA-targeting medicines aimed at treating oncology and neurological disorders. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This innovative approach enables the design of small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Rgenta's unique methodology aims to unlock the therapeutic potential of previously undruggable targets, ultimately advancing drug development for human diseases.
Alioth
Series A in 2022
Alioth specializes in the development and application of pharmaceutical process technology, focusing on high-quality separation and purification solutions for the pharmaceutical and biotechnology sectors. The company is committed to ensuring compliance with domestic and international regulations, particularly Good Manufacturing Practices (GMP). To support its operations, Alioth has established production facilities in Lingang, Shanghai, and Hangzhou, which house process development labs, verification labs, and research and development centers dedicated to filtration technology. The team, comprised of membrane technology scientists, plays a crucial role in advancing the company’s product offerings and enhancing supply chain security. Through its innovative solutions, Alioth aims to improve pharmaceutical manufacturing processes for its partners.
Onechip Bioelectronics
Series B in 2022
Wanzhong Yixin Biotechnology is a developer of semiconductor integrated circuit biosensor chips and other related devices. The company's biosensor chip products are used in emerging fields such as genetic testing, water quality monitoring, and environmental protection IoT monitoring.
Yudao Bio
Series A in 2022
Yudo Bio provides biopharmaceutical products. It has its headquarters in Shanghai in China.
Nutshell Therapeutics
Series A in 2022
Nutshell Therapeuticstein drug discovery platform, composed of a well-integrated set of computational modules and experimental tools based on a proprietary AI algorithm and deep know-how derived from biochemistry and biophysics, possesses the capability to discover a host of drug entities, including various types of protein activators and subtype/mutation-selective small molecules.
Lingyi Biology
Seed Round in 2022
Lingyi Biology is a gene therapy company that uses a platform to validate the functionality of animal models of rare diseases. It is dedicated to sourcing innovation, with a focus on genetic rare diseases like metabolism, CNS, and ophthalmology. Lingyi Biology has a gene therapy and rare disease discovery, development, and industrialization team, as well as a rare disease animal model preparation and verification platform, to address the pain point of a lack of effective animal models for rare disease research and development.
Ucello Therapeutics
Series A in 2022
Ucello Therapeutics focuses on the development of allogeneic cell therapies utilizing its proprietary CAR-T cell technology platform, known as CBT-X20. The company aims to create universal CAR-T cell therapeutic drugs that address unmet clinical needs in cancer treatment. By leveraging advanced gene and cell therapy technologies, Ucello's therapies target cancer cells at the molecular level, making them accessible to patients with varying lymphocyte levels and those with a history of transplant relapse. This innovative approach allows for effective cancer gene therapies to be administered to individuals with specific pre-existing medical conditions.
Vibrant
Venture Round in 2022
Vibrant develops an AI drug development platform to focus on building immune system-related drug pipelines. The company will use artificial intelligence algorithms to accelerate the efficiency of drug development in various aspects such as target discovery, drug design, and drug efficacy evaluation; at the same time, the company expects to continuously improve the success rate of drug development through sustainable data accumulation and algorithm optimization.
It was founded and headed by Dr. Wang Luquan and is based in Guangzhou, Guangdong, China.
Protoga
Seed Round in 2021
Protoga is a biotechnology company specializing in the development and commercialization of microalgae-based products aimed at enhancing human immunity. The firm focuses on large-scale microalgae cultivation and offers contract development and manufacturing organization (CDMO) services. Protoga's products are meticulously cultivated and processed to ensure high quality and consistency, incorporating beneficial compounds such as β-1,3-Glucan, microalgal protein, DHA, and astaxanthin. The company's customer base spans various industries, including food, healthcare, and cosmetics, reflecting its commitment to providing innovative solutions derived from microalgae biosynthesis technology.
Kyinno
Series A in 2021
Kyinno is a biopharmaceutical company specializing in the development of oncology drugs. Its focus lies in immune treatments against cancer and next-generation kinase inhibitor design.
Triastek
Series B in 2021
Triastek Co. Ltd., established in 2015 and headquartered in Nanjing, China, specializes in the manufacturing of 3D printed pharmaceuticals and related medical equipment. The company offers a range of drugs, including blockbuster and orphan drugs, along with complex drug delivery technologies. Triastek's portfolio includes 3D drug printing services, such as formulation design, equipment, and development methods, with patents secured in key global markets like China, the US, Europe, and Japan. Notably, the company owns Melt Extrusion Deposition (MED), a universally applicable 3D printing technology for solid formulations. Triastek's mission is to revolutionize drug delivery, development, and manufacturing through its proprietary 3D printing technology.
NeuraMatrix
Series A in 2021
NeuraMatrix is an innovative developer of brain-computer interface technology, specializing in advanced neural interfaces that facilitate communication between humans and computers. The company's comprehensive approach includes both hardware and software solutions, aiming to enhance human interaction with technology and advance research in brain science and neurological diseases. NeuraMatrix focuses on improving diagnosis, treatment, and drug development for neurological conditions while leveraging the significant commercial potential of its brain-computer interface technologies. Recently, the company secured significant funding to support research and development efforts, including the update of R&D equipment, mass production of chips, product iterations, and market promotion. Through its pioneering efforts, NeuraMatrix is positioned to influence the future of neuroscience research and its practical applications.
Zhongke Guosheng
Angel Round in 2021
Zhongke Guosheng is research and development firm that designs and manufactures furan-based bio-based materials.
Insyce
Series A in 2021
Insyce creates equipment and apparatus for science. Its business strives to provide tools and technology for bio labs that monitor the environment to deliver accurate data and speedy chemical analysis while keeping lab costs down for their clients. It is dedicated to providing upper biological separation equipment and chemical analysis tools for global clients, cutting down on client operating expenses, and adding value for clients.
Excell Biology
Series B in 2021
Excell Biology is dedicated to addressing the biomedical industry's blockage and accomplishing the localization of essential raw materials. It offers customers biological medicine, cell, and gene therapy, and fundamental scientific research products and services of the quality and concentrates on three product sectors, including serum-free medium, fetal bovine serum, and identification reagents.
Joes Future Food
Series A in 2021
Joes Future Food engages the development, production, testing, and sales of raw and auxiliary materials for food and biological products.
RootPath Genomics
Series B in 2021
RootPath Genomics, Inc. is a biotechnology company founded in 2017 and headquartered in Cambridge, Massachusetts. The company specializes in developing a next-generation T-cell therapy platform that integrates precision medicine with cancer immunotherapy. By focusing on the analysis and manipulation of individual immune cells, RootPath aims to enhance immune responses and improve cell therapy efficacy. Its innovative technologies allow for precise monitoring and modulation of the immune system, which is intended to revolutionize the diagnosis and treatment of cancer.
Centaur Labs
Series A in 2021
Centaur Labs provides a platform for expert data annotation services, specializing in medical, scientific, and other complex datasets. It leverages a global network of tens of thousands of students and professionals to deliver accurate and scalable solutions.
Scivita Medical
Series B in 2021
Scivita Medical is a high-tech enterprise specializing in optical diagnosis and treatment, as well as the development of multidimensional imaging technologies and high-performance materials. The company focuses on precision manufacturing for minimally invasive medical procedures and is recognized for its advancements in endoscopy technology. Scivita Medical offers a range of products that include flexible and rigid endoscopes, featuring innovations such as ultra-high-definition visualization, 3D imaging, and specialized light visualization techniques, including fluorescence. Its portfolio encompasses various medical devices, including 4K medical endoscope camera systems, integrated endoscope systems, and single-use electronic instruments like hysteroscopes, bladder pyeloscopes, and bronchoscopes. These products are designed to provide healthcare professionals with efficient tools for diagnosis and treatment, enhancing the capabilities of modern endoscopic procedures.
Bota Biosciences
Series B in 2021
Bota Biosciences is a global industrial biotechnology company based in Hangzhou, China, founded in 2019. The company specializes in synthetic bioengineering technology for bio-manufacturing, focusing on developing efficient, eco-friendly, and cost-effective biomanufacturing processes. Bota has created an integrative bioengineering platform that connects biological design with scale-up manufacturing, facilitating the production of high-performing industrial compounds through advanced fermentation processes. To support its innovative solutions, Bota has established a pilot plant and manufacturing facility, which enables the company to deliver scalable industrial solutions and market-ready products. Its infrastructure is designed to assist customers and partners across various industries, including nutrition, food, personal care, and animal health. Bota Biosciences is committed to accelerating shifts toward sustainable living by leveraging its multidisciplinary team's expertise to drive impactful biotech innovations.
Jyss Bio
Series B in 2021
Jyss Bio is a developer of disposable bioreactors and peripheral equipment.
PAQ Therapeutics
Series A in 2021
PAQ Therapeutics is a biotechnology company focused on innovating health restoration and disease treatment through the process of autophagy, which is the body's natural mechanism for cellular degradation. The company is developing a unique class of small-molecule degraders utilizing autophagosome-tethering compound technology. This approach allows for the binding of various substrates to the autophagy pathway, thereby enabling the creation of targeted therapies. By harnessing this mechanism, PAQ Therapeutics aims to provide solutions for serious diseases that currently have limited therapeutic options available to patients.
GRIT Biotechnology
Series A in 2021
GRIT Biotechnology, established in 2019 and based in Shanghai, China, specializes in the research and development of Tumor Infiltration Lymphocytes (TIL) immunotherapy for treating solid tumors. The company aims to enhance cancer therapies by focusing on this innovative approach.
Triastek
Series B in 2021
Triastek Co. Ltd., established in 2015 and headquartered in Nanjing, China, specializes in the manufacturing of 3D printed pharmaceuticals and related medical equipment. The company offers a range of drugs, including blockbuster and orphan drugs, along with complex drug delivery technologies. Triastek's portfolio includes 3D drug printing services, such as formulation design, equipment, and development methods, with patents secured in key global markets like China, the US, Europe, and Japan. Notably, the company owns Melt Extrusion Deposition (MED), a universally applicable 3D printing technology for solid formulations. Triastek's mission is to revolutionize drug delivery, development, and manufacturing through its proprietary 3D printing technology.
Nutshell Therapeutics
Series A in 2021
Nutshell Therapeuticstein drug discovery platform, composed of a well-integrated set of computational modules and experimental tools based on a proprietary AI algorithm and deep know-how derived from biochemistry and biophysics, possesses the capability to discover a host of drug entities, including various types of protein activators and subtype/mutation-selective small molecules.
NiKang Therapeutics
Series C in 2021
NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and headquartered in Wilmington, Delaware. The company specializes in the discovery and development of small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. Utilizing a discovery approach informed by target structure biology, NiKang employs structure-based drug design to facilitate the rapid and efficient development of proprietary drug candidates. This methodology enables the company to create innovative therapies with desirable pharmacological properties, ultimately aimed at improving the lives of patients through enhanced treatment options.
Jyss Bio
Series A in 2021
Jyss Bio is a developer of disposable bioreactors and peripheral equipment.
Scivita Medical
Series A in 2021
Scivita Medical is a high-tech enterprise specializing in optical diagnosis and treatment, as well as the development of multidimensional imaging technologies and high-performance materials. The company focuses on precision manufacturing for minimally invasive medical procedures and is recognized for its advancements in endoscopy technology. Scivita Medical offers a range of products that include flexible and rigid endoscopes, featuring innovations such as ultra-high-definition visualization, 3D imaging, and specialized light visualization techniques, including fluorescence. Its portfolio encompasses various medical devices, including 4K medical endoscope camera systems, integrated endoscope systems, and single-use electronic instruments like hysteroscopes, bladder pyeloscopes, and bronchoscopes. These products are designed to provide healthcare professionals with efficient tools for diagnosis and treatment, enhancing the capabilities of modern endoscopic procedures.
Advaccine
Private Equity Round in 2021
Advaccine is a biotechnology company dedicated to the discovery and development of innovative vaccines, targeting both preventive and therapeutic applications. The company focuses on addressing unmet clinical needs globally, with a portfolio that includes first-in-class products. Advaccine is actively developing viral vaccine technologies aimed at various diseases, including hepatitis B, respiratory syncytial virus, type 1 diabetes, and coronavirus. Through its research pipeline, Advaccine aims to provide healthcare providers with effective solutions to improve patient outcomes.
Qihan Biotech
Series A in 2021
Qihan Biotech is a biomedical company specializing in genetic technology with a focus on addressing the global shortage of organ donors. The company aims to produce safe and effective cells, tissues, and organs for human transplantation using advanced gene editing techniques. By applying these technologies to xenogenic organ transplantation, Qihan Biotech seeks to create organs that can be transplanted into humans, thereby reducing the need for traditional organ transplants and saving lives.
NovoCodex
Series A in 2021
NovoCodex is involved in the research, development, and manufacture of biological products. Its mission is to provide cutting-edge technology to meet clinical needs. In Binhai New City Science and Technology Park, the company has established a biopharmaceutical laboratory with experience and capabilities in genetic engineering construction, cell culture, toxin synthesis, ADC coupling, preparation filling, preclinical research, and clinical research.
NeuraMatrix
Seed Round in 2021
NeuraMatrix is an innovative developer of brain-computer interface technology, specializing in advanced neural interfaces that facilitate communication between humans and computers. The company's comprehensive approach includes both hardware and software solutions, aiming to enhance human interaction with technology and advance research in brain science and neurological diseases. NeuraMatrix focuses on improving diagnosis, treatment, and drug development for neurological conditions while leveraging the significant commercial potential of its brain-computer interface technologies. Recently, the company secured significant funding to support research and development efforts, including the update of R&D equipment, mass production of chips, product iterations, and market promotion. Through its pioneering efforts, NeuraMatrix is positioned to influence the future of neuroscience research and its practical applications.
Senti Biosciences
Series B in 2021
Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.
Joes Future Food
Angel Round in 2020
Joes Future Food engages the development, production, testing, and sales of raw and auxiliary materials for food and biological products.
nference
Series C in 2020
nference is a technology company that develops AI-based software platforms for transforming biomedical knowledge. It synthesizes structured and unstructured data from various sources, offering real-time insights through neural networks. The company provides services in drug discovery, lifecycle management, and precision medicine.
Nuance Biotech
Series D in 2020
Nuance Biotech Inc. is a pharmaceutical development company based in Shanghai, China, founded in 2014. The company focuses on the research and development of innovative drug formulations, offering products in the form of capsules, injections, and tubes. In addition to its core pharmaceutical development activities, Nuance Biotech also provides commercial and academic platforms for drug-related ventures and offers contract sales organization services. Through its diverse capabilities, the company aims to advance healthcare solutions and contribute to the pharmaceutical industry.
GRIT Biotechnology
Series A in 2020
GRIT Biotechnology, established in 2019 and based in Shanghai, China, specializes in the research and development of Tumor Infiltration Lymphocytes (TIL) immunotherapy for treating solid tumors. The company aims to enhance cancer therapies by focusing on this innovative approach.
Tallac Therapeutics
Series A in 2020
Tallac Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative immunotherapies for cancer patients. Founded in 2018 and headquartered in Burlingame, California, the company specializes in creating conjugates of antibodies combined with potent toll-like receptor agonists. This approach aims to activate both innate and adaptive immunity, enabling targeted immune responses against various solid tumor malignancies. Through its advanced therapies, Tallac Therapeutics seeks to enhance the immune system's ability to combat cancer more effectively.
Biostar Technologies
Series E in 2020
Beijing Biostar Technologies, Ltd., established in 2002, is a biopharmaceutical company based in Beijing, China. It specializes in the development of anti-tumor chemotherapy biopharmaceutical molecules, with a focus on creating innovative small molecule chemical drugs for cancer treatment. The company was founded by a team of Chinese scientists led by Dr. Tang Li and Dr. Qiu Rongguo, who previously worked in the United States. Biostar Technologies pioneered the creation of new anti-cancer drugs based on epothilone in China and its technology is recognized as being at the international advanced level.
D3 Bio
Series A in 2020
D3 Bio, established in 2020, is a biotechnology company headquartered in China. It specializes in the development and registration of innovative medicines, primarily focusing on oncology and immunology. The company's approach involves analyzing clinical and market data to identify gaps in current treatments, employing unique drug development methodologies to target new disease areas and routes, and ultimately providing patients with alternative therapeutic options.
GeneCast Biotechnology
Series E in 2020
GeneCast Biotechnology Co., Ltd. is a Beijing-based company founded in 2014, specializing in gene research and cancer diagnostics. The company offers a technology platform for cell-free DNA next-generation sequencing (NGS) tests, which include companion diagnostics, genetic profiling, prognosis, and monitoring for various solid tumors. GeneCast provides solutions for cancer treatment and genetic testing, focusing on tumors such as lung, colorectal, liver, and breast cancers. Its non-invasive diagnostic methods leverage high-throughput sequencing and bioinformatics to enable personalized medicine, aiming to improve patient outcomes and quality of life. The company collaborates with hospitals and research institutions to advance its capabilities in detecting tumors and cancer-related genes in blood.
Advaccine
Series B in 2020
Advaccine is a biotechnology company dedicated to the discovery and development of innovative vaccines, targeting both preventive and therapeutic applications. The company focuses on addressing unmet clinical needs globally, with a portfolio that includes first-in-class products. Advaccine is actively developing viral vaccine technologies aimed at various diseases, including hepatitis B, respiratory syncytial virus, type 1 diabetes, and coronavirus. Through its research pipeline, Advaccine aims to provide healthcare providers with effective solutions to improve patient outcomes.
Taimei Technology
Venture Round in 2020
Taimei Technology is a digital innovator specializing in research and development within the life science industry. The company offers an integrated digital platform that leverages AI, big data, cloud computing, and mobile internet technologies to provide innovative solutions across the full product lifecycle.
InventisBio
Series D in 2020
InventisBio Inc. is a biotechnology company focused on discovering and developing innovative therapeutics for cancer and metabolic diseases. Founded in 2013 and based in Pudong, China, the company has developed a range of small molecule drug candidates targeting lung cancer, breast cancer, and gout. Among its notable products is D-0316, a third-generation EGFR-T790M tyrosine kinase inhibitor. InventisBio is also engaged in creating targeted immuno-oncology therapies that can be used in combination with existing treatments, such as PD-1 antibodies, to address various cancer indications. Co-founded by Dr. Yaolin Wang and a team of scientists with extensive experience in drug discovery at major pharmaceutical companies, InventisBio aims to provide effective therapies for significant health challenges.
Bota Biosciences
Series A in 2020
Bota Biosciences is a global industrial biotechnology company based in Hangzhou, China, founded in 2019. The company specializes in synthetic bioengineering technology for bio-manufacturing, focusing on developing efficient, eco-friendly, and cost-effective biomanufacturing processes. Bota has created an integrative bioengineering platform that connects biological design with scale-up manufacturing, facilitating the production of high-performing industrial compounds through advanced fermentation processes. To support its innovative solutions, Bota has established a pilot plant and manufacturing facility, which enables the company to deliver scalable industrial solutions and market-ready products. Its infrastructure is designed to assist customers and partners across various industries, including nutrition, food, personal care, and animal health. Bota Biosciences is committed to accelerating shifts toward sustainable living by leveraging its multidisciplinary team's expertise to drive impactful biotech innovations.
NiKang Therapeutics
Series B in 2020
NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and headquartered in Wilmington, Delaware. The company specializes in the discovery and development of small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. Utilizing a discovery approach informed by target structure biology, NiKang employs structure-based drug design to facilitate the rapid and efficient development of proprietary drug candidates. This methodology enables the company to create innovative therapies with desirable pharmacological properties, ultimately aimed at improving the lives of patients through enhanced treatment options.
Rgenta Therapeutics
Seed Round in 2020
Rgenta Therapeutics, Inc. is a biotechnology company focused on developing RNA-targeting medicines aimed at treating oncology and neurological disorders. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This innovative approach enables the design of small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Rgenta's unique methodology aims to unlock the therapeutic potential of previously undruggable targets, ultimately advancing drug development for human diseases.
nference
Series B in 2020
nference is a technology company that develops AI-based software platforms for transforming biomedical knowledge. It synthesizes structured and unstructured data from various sources, offering real-time insights through neural networks. The company provides services in drug discovery, lifecycle management, and precision medicine.
RootPath Genomics
Series A in 2020
RootPath Genomics, Inc. is a biotechnology company founded in 2017 and headquartered in Cambridge, Massachusetts. The company specializes in developing a next-generation T-cell therapy platform that integrates precision medicine with cancer immunotherapy. By focusing on the analysis and manipulation of individual immune cells, RootPath aims to enhance immune responses and improve cell therapy efficacy. Its innovative technologies allow for precise monitoring and modulation of the immune system, which is intended to revolutionize the diagnosis and treatment of cancer.
Lansion Biotechnology
Series C in 2019
Lansion Biotechnology is specialized in research & development, production, sell, services of in vitro diagnostic reagents and devices. With its advanced technology concept, Lansionbio provides equioment, reagents and services to world-wild clients according to their needs.
GeneCast Biotechnology
Series D in 2019
GeneCast Biotechnology Co., Ltd. is a Beijing-based company founded in 2014, specializing in gene research and cancer diagnostics. The company offers a technology platform for cell-free DNA next-generation sequencing (NGS) tests, which include companion diagnostics, genetic profiling, prognosis, and monitoring for various solid tumors. GeneCast provides solutions for cancer treatment and genetic testing, focusing on tumors such as lung, colorectal, liver, and breast cancers. Its non-invasive diagnostic methods leverage high-throughput sequencing and bioinformatics to enable personalized medicine, aiming to improve patient outcomes and quality of life. The company collaborates with hospitals and research institutions to advance its capabilities in detecting tumors and cancer-related genes in blood.
Ansun Biopharma
Series B in 2019
Ansun Biopharma is a clinical-stage biopharmaceutical company based in San Diego that develops host-directed anti-viral therapies to prevent and treat life-threatening respiratory infections. The company focuses on therapies targeting the host rather than the virus, aiming to overcome viral mutation and immune evasion. Its pipeline includes Fludase, candidate for prophylaxis and treatment of influenza and parainfluenza infections, and Viradin, an intravenous therapy for sepsis, septic shock, and certain viral hemorrhagic fevers. It also advances TOSAP formulation technology to create microspheres and nanospheres for drug delivery. Through these programs, Ansun Biopharma seeks to provide therapies for severe viral diseases where traditional antivirals face limitations.
Chameleon Biosciences
Seed Round in 2019
Chameleon Biosciences Inc. is a biotechnology company focused on developing Adeno Associated Virus (AAV) based gene therapies aimed at treating rare genetic diseases. Founded in 2017 and headquartered in San Anselmo, California, the company utilizes innovative gene delivery technology to effectively administer therapeutic proteins to targeted tissues while minimizing immune responses to both the delivery vector and the therapeutic agents. This approach enhances gene delivery efficiency, reduces the immunogenicity of treatments, and expands the potential applications for patients with genetic disorders. Chameleon Biosciences is dedicated to addressing the significant challenges posed by genetic diseases, particularly in children, and strives to provide effective treatment options that allow for multiple systemic dose administrations, ensuring that affected individuals receive personalized care as their conditions evolve.
Chemclin
Private Equity Round in 2018
Chemclin Biotech is a Chinese technical service provider specializing in in-vitro diagnostic instruments and auxiliary reagents for clinical diagnosis. The company develops, produces, and sells clinical immunochemiluminescence diagnostic testing reagents and instruments. Its service offerings encompass clinical inspection instruments, various types of auxiliary reagents, technical support, management and certification, as well as the operation of independent medical laboratories. Chemclin is committed to introducing advanced diagnostic products and services to the Chinese market, thereby enhancing the capabilities of clinical diagnostics in the region.
Si'ao Biotechnology
Series A in 2018
Si'ao Biotechnology engages in the development and production of genetic engineering vaccines and test kits.
GrandOmics
Series B in 2018
GrandOmics is a biotechnology company that specializes in molecular diagnostics and genetic testing services, primarily targeting single-gene diseases. The company develops and utilizes advanced sequencing technologies, including single-molecule, real-time sequencing, to enhance disease detection. GrandOmics offers a comprehensive platform known as GrandBox, which integrates clinical sample management, data standard analysis, and visualization reporting. This platform serves as a centralized solution for clinical laboratories, enabling efficient management and analysis of genetic disease sequencing data. Through its innovative approach, GrandOmics aims to provide accurate, reliable, and scientifically rigorous genetic testing services that support both research and clinical applications.
Adlai Nortye
Series B in 2018
Adlai Nortye Biopharma Co., Ltd. is a clinical-stage biopharmaceutical company based in Hangzhou, China, specializing in the research and development of innovative oncology therapies. Founded in 2004 and formerly known as Sinopep Pharmaceutical Inc., the company focuses on developing cancer treatments and addressing metabolic diseases. Adlai Nortye operates R&D and clinical operation centers in both China and the United States, emphasizing its global approach to drug development. The company has established a robust pipeline featuring over ten drug candidates, including those in various stages of clinical and preclinical development, such as buparlisib, palupiprant, and AN4005. Through collaborations and internal discoveries, Adlai Nortye seeks to advance its goal of providing effective treatment options for patients with a wide range of tumor types.
nference
Series A in 2018
nference is a technology company that develops AI-based software platforms for transforming biomedical knowledge. It synthesizes structured and unstructured data from various sources, offering real-time insights through neural networks. The company provides services in drug discovery, lifecycle management, and precision medicine.
Ansun Biopharma
Series A in 2018
Ansun Biopharma is a clinical-stage biopharmaceutical company based in San Diego that develops host-directed anti-viral therapies to prevent and treat life-threatening respiratory infections. The company focuses on therapies targeting the host rather than the virus, aiming to overcome viral mutation and immune evasion. Its pipeline includes Fludase, candidate for prophylaxis and treatment of influenza and parainfluenza infections, and Viradin, an intravenous therapy for sepsis, septic shock, and certain viral hemorrhagic fevers. It also advances TOSAP formulation technology to create microspheres and nanospheres for drug delivery. Through these programs, Ansun Biopharma seeks to provide therapies for severe viral diseases where traditional antivirals face limitations.
Taimei Technology
Series D in 2018
Taimei Technology is a digital innovator specializing in research and development within the life science industry. The company offers an integrated digital platform that leverages AI, big data, cloud computing, and mobile internet technologies to provide innovative solutions across the full product lifecycle.
23Mofang
Series B in 2018
23Mofang is a company specializing in genetic testing services tailored for the Chinese population. It manufactures saliva-based testing kits that allow users to assess their ancestral origins, genetic risks, and traits. By evaluating samples, the company provides detailed reports through a mobile application, facilitating early intervention for potential health issues. Furthermore, 23Mofang integrates Internet technology with genetic testing to create a comprehensive database of life data, with the mission of enhancing health benefits for individuals and communities. The company aims to establish itself as a reliable technology enterprise in the field of genetic testing and life data analysis.
GeneCast Biotechnology
Series C in 2018
GeneCast Biotechnology Co., Ltd. is a Beijing-based company founded in 2014, specializing in gene research and cancer diagnostics. The company offers a technology platform for cell-free DNA next-generation sequencing (NGS) tests, which include companion diagnostics, genetic profiling, prognosis, and monitoring for various solid tumors. GeneCast provides solutions for cancer treatment and genetic testing, focusing on tumors such as lung, colorectal, liver, and breast cancers. Its non-invasive diagnostic methods leverage high-throughput sequencing and bioinformatics to enable personalized medicine, aiming to improve patient outcomes and quality of life. The company collaborates with hospitals and research institutions to advance its capabilities in detecting tumors and cancer-related genes in blood.
Qrativ
Series A in 2017
Qrativ Inc., established in 2017 and headquartered in Cambridge, Massachusetts, specializes in developing an AI-driven healthcare platform focused on identifying potential treatments for rare diseases. The company's core product is a drug purposing platform designed to revolutionize how therapies for unmet medical needs are discovered and developed. This platform, Darwin.ai, employs machine learning and artificial intelligence to uncover new uses for existing molecules, aiming to provide treatments for conditions where market-available drugs are lacking. Qrativ serves biotechnology and pharmaceutical companies with this innovative solution.
Nuance Biotech
Series A in 2017
Nuance Biotech Inc. is a pharmaceutical development company based in Shanghai, China, founded in 2014. The company focuses on the research and development of innovative drug formulations, offering products in the form of capsules, injections, and tubes. In addition to its core pharmaceutical development activities, Nuance Biotech also provides commercial and academic platforms for drug-related ventures and offers contract sales organization services. Through its diverse capabilities, the company aims to advance healthcare solutions and contribute to the pharmaceutical industry.
Taimei Technology
Series C in 2017
Taimei Technology is a digital innovator specializing in research and development within the life science industry. The company offers an integrated digital platform that leverages AI, big data, cloud computing, and mobile internet technologies to provide innovative solutions across the full product lifecycle.
TopGene
Series A in 2016
TopGene is a biotechnology company based in Guangzhou, China, established in 2014. It specializes in genomics technology applied to human medicine and life sciences, focusing on genetic testing, molecular diagnostics, and companion diagnostics for various diseases, including chromosomal disorders, hereditary deafness, metabolic diseases in newborns, and multiple cancer types. TopGene offers next-generation sequencing, DNA/RNA extraction services, and targeted re-sequencing to a diverse clientele, including academic institutions, biotechnology firms, government agencies, and pharmaceutical companies. The company emphasizes a patient-centered approach and aims to enhance human health through integrated services that combine scientific research with clinical applications. By promoting the clinical application of precision medicine, TopGene contributes to advancements in the fields of genetics and healthcare both in China and internationally.
GrandOmics
Venture Round in 2016
GrandOmics is a biotechnology company that specializes in molecular diagnostics and genetic testing services, primarily targeting single-gene diseases. The company develops and utilizes advanced sequencing technologies, including single-molecule, real-time sequencing, to enhance disease detection. GrandOmics offers a comprehensive platform known as GrandBox, which integrates clinical sample management, data standard analysis, and visualization reporting. This platform serves as a centralized solution for clinical laboratories, enabling efficient management and analysis of genetic disease sequencing data. Through its innovative approach, GrandOmics aims to provide accurate, reliable, and scientifically rigorous genetic testing services that support both research and clinical applications.
Taimei Technology
Series B in 2016
Taimei Technology is a digital innovator specializing in research and development within the life science industry. The company offers an integrated digital platform that leverages AI, big data, cloud computing, and mobile internet technologies to provide innovative solutions across the full product lifecycle.
Taimei Technology
Series A in 2016
Taimei Technology is a digital innovator specializing in research and development within the life science industry. The company offers an integrated digital platform that leverages AI, big data, cloud computing, and mobile internet technologies to provide innovative solutions across the full product lifecycle.
nference
Seed Round in 2016
nference is a technology company that develops AI-based software platforms for transforming biomedical knowledge. It synthesizes structured and unstructured data from various sources, offering real-time insights through neural networks. The company provides services in drug discovery, lifecycle management, and precision medicine.
ET Healthcare
Series B in 2015
ET Healthcare is a medical diagnostics company focused on automated immunodiagnostics. It develops central laboratory analyzers and near-patient testing solutions, with the Pylon Immunochemistry System designed to bring immunoassay performance closer to point-of-care. The system integrates central laboratory capabilities for immunoassays addressing inflammation, cardiac function, fertility, infectious diseases, and tumors, and includes BNP Immunoassay for heart failure management. The company operates from Palo Alto, California, with offices in Shanghai and manufacturing facilities in Suzhou, China. Its products aim to reduce facility space, plumbing, electricity needs, and staffing requirements while enabling high-sensitivity assays and streamlined blood analysis for a range of clinical settings, including hospitals and clinics.
ETComm
Series A in 2015
ETComm is a biotech firm focused on developing compact digital health products for hospitals. The company specializes in creating innovative digital health solutions such as digital electrocardiographs, body fat measurement instruments, and Bluetooth blood pressure monitors. These products are designed to provide reliable tools for medical practitioners to enhance patient health. ETComm also offers a community smart medical service solution that acts as a health gatekeeper, automatically linking various types of electronic gear without manual operation. Additionally, the company provides direct health product OEM services, technical support, and background data analysis services through its industry integrators.
ET Healthcare
Series A in 2014
ET Healthcare is a medical diagnostics company focused on automated immunodiagnostics. It develops central laboratory analyzers and near-patient testing solutions, with the Pylon Immunochemistry System designed to bring immunoassay performance closer to point-of-care. The system integrates central laboratory capabilities for immunoassays addressing inflammation, cardiac function, fertility, infectious diseases, and tumors, and includes BNP Immunoassay for heart failure management. The company operates from Palo Alto, California, with offices in Shanghai and manufacturing facilities in Suzhou, China. Its products aim to reduce facility space, plumbing, electricity needs, and staffing requirements while enabling high-sensitivity assays and streamlined blood analysis for a range of clinical settings, including hospitals and clinics.
Aegis
Series B in 2011
Aegis Petroleum Technology Co., Ltd. is a Sino-foreign joint high-tech venture established in 2009 in Zhangjiang High-tech Park, Shanghai. The company specializes in sewage treatment services, particularly focusing on oil field waste, such as drilling fluid, fracturing underground wastewater, and wastewater from tertiary oil recovery processes. Aegis integrates proprietary technology and comprehensive equipment for sewage disposal, enabling it to provide one-stop services that include conceptual design, installation, and trial operation of treatment systems. The company prides itself on its intellectual property rights and its capability to deliver integrated solutions in wastewater management, positioning itself as an innovative player in the environmental technology sector.
nkf-pharma
Venture Round in 2011
Nanjing King-friend Biochemical Pharmaceutical is focused on research, production, and sales of raw material medicines of heparin sodium. It mainly produces a series of products including heparin sodium and low molecular heparin.
Nanjing King-friend Biochemical Pharmaceutical was restructured and founded in March 2005. As of today, it owns two subsidiaries and two holding subsidiaries and its registered capital is 36 million. Its output of heparin sodium accounts for 20% of the world’s heparin sodium.
Aegis
Series A in 2010
Aegis Petroleum Technology Co., Ltd. is a Sino-foreign joint high-tech venture established in 2009 in Zhangjiang High-tech Park, Shanghai. The company specializes in sewage treatment services, particularly focusing on oil field waste, such as drilling fluid, fracturing underground wastewater, and wastewater from tertiary oil recovery processes. Aegis integrates proprietary technology and comprehensive equipment for sewage disposal, enabling it to provide one-stop services that include conceptual design, installation, and trial operation of treatment systems. The company prides itself on its intellectual property rights and its capability to deliver integrated solutions in wastewater management, positioning itself as an innovative player in the environmental technology sector.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.